| 摘要: |
| ［摘要］ 目的 观察斯鲁利单抗对非小细胞肺癌（NSCLC）的临床疗效及对T细胞功能的影响。方法 招募2022年12月至2024年4月泰州市人民医院收治的NSCLC患者162例，根据患者治疗意愿分为斯鲁利单抗治疗组（58例）和常规化疗组（104例）。常规化疗组接受以铂类为主的同步化疗方案，斯鲁利单抗治疗组在常规化疗组治疗方案基础上给予斯鲁利单抗治疗，所有患者均连续治疗2个周期（3周为1个治疗周期）。比较两组患者治疗前后T细胞亚群、肿瘤标志物水平。根据实体瘤疗效评价标准1.1版（RECIST 1.1）评估治疗效果。经1年随访，比较两组无进展生存期及不良反应发生情况。结果 两组治疗后血清癌胚抗原（CEA）、糖类抗原（CA）125、CA199、细胞角质蛋白19片段抗原21-1（CYFRA21-1）水平均较治疗前显著降低（P<0.05），但两组间比较差异无统计学意义（P>0.05）。相比于常规化疗组，斯鲁利单抗治疗组治疗后的CD4+、CD4+/CD8+比值水平更高，差异有统计学意义（P<0.05）。斯鲁利单抗治疗组患者客观缓解率、疾病控制率显著高于常规化疗组（58.62% vs 37.50%， χ2=6.709，P=0.010；82.76% vs 60.58%， χ2=8.493，P=0.004）。斯鲁利单抗治疗组和常规化疗组的中位无进展生存期分别为12个月和9个月，斯鲁利单抗治疗组无进展生存预后显著优于常规化疗组（log-rank检验： χ2=10.931，P=0.001）。两组不良反应总发生率比较差异无统计学意义（P>0.05）。结论 斯鲁利单抗对NSCLC具有较好的临床治疗效果，可有效改善患者T细胞免疫功能和血清肿瘤标志物水平，具有临床推广价值。 |
| 关键词: 斯鲁利单抗 非小细胞肺癌 T细胞功能 临床疗效 |
| DOI：10.3969/j.issn.1674-3806.2025.12.13 |
| 分类号:R 734.2 |
| 基金项目:江苏省卫生健康委员会科研项目（编号：20210326） |
|
| Observation on clinical efficacy of serplulimab in non-small cell lung cancer and its influence on T cell function |
|
YANG Xiuyuan, YU Lei
|
|
Department of Oncology, Taizhou People′s Hospital, Taizhou 225300, China
|
| Abstract: |
| ［Abstract］ Objective To observe the clinical efficacy of serplulimab in non-small cell lung cancer(NSCLC) and its influence on T cell function. Methods A total of 162 patients with NSCLC who were admitted to Taizhou People′s Hospital from December 2022 to April 2024 were recruited and divided into serplulimab treatment group(58 patients) and conventional chemotherapy group(104 patients) according to the patients′ treatment intentions. The conventional chemotherapy group received a platinum-based concurrent chemotherapy regimen, while the serplulimab treatment group received the same chemotherapy regimen as the conventional chemotherapy group plus an additional serplulimab treatment. All the patients were treated continuously for 2 cycles(3 weeks as 1 treatment cycle). The levels of T lymphocyte subsets and tumor markers were compared between the patients in the two groups before and after treatment. The therapeutic effects were evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1). After a one-year follow-up, the progression-free survival and the occurrence of adverse reactions were compared between the two groups. Results After treatment, the levels of serum carcinoembryonic antigen(CEA), carbohydrate antigen 125(CA125), carbohydrate antigen 199(CA199) and cytokeratin fragment antigen 21-1(CYFRA21-1) in both groups were significantly lower than those before treatment(P<0.05), but there were no statistically significant differences in the levels of these indicators between the two groups after treatment(P>0.05). Compared with those in the conventional chemotherapy group, the levels of CD4+ and CD4+/CD8+ ratio in the serplulimab treatment group were higher after treatment(P<0.05), and the differences were statistically significant(P<0.05). The objective response rate and disease control rate of the patients in the serplulimab treatment group were significantly higher than those in the conventional chemotherapy group(58.62% vs 37.50%, χ2=6.709, P=0.010; 82.76% vs 60.58%, χ2=8.493, P=0.004). The median progression-free survival in the serplulimab treatment group was 12 months and that in the conventional chemotherapy group was 9 months. The prognosis of progression-free survival in the serplulimab treatment group was significantly better than that in the conventional chemotherapy group(log-rank test: χ2=10.931, P=0.001). There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Serplulimab has good clinical therapeutic effects on NSCLC. It can effectively improve T lymphocyte immune function and levels of serum tumor markers in the NSCLC patients, and has clinical promotion value. |
| Key words: Serplulimab Non-small cell lung cancer(NSCLC) T cell function Clinical efficacy |
